Evidence map›Paper›PMID 37362385›Full record

ArticleJournal of the Endocrine Society2023

Variant Tyr 394Ser in the

Lior Tolkin, Vanessa Klein, Meir Frankel, Gheona Altarescu, Rachel Beeri, Gabriel Munter

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. A Knock-In Mouse Model of theJournal of the Endocrine Society · 2023
    Article
  4. Frontiers in endocrinology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lior TolkinDepartment of Internal Medicine Endocrine Unit, Shaare Zedek Medical Center Jerusalem affiliated with the Faculty of Medicine, Hebrew University, Jerusalem 3235, Israel.ORCID https://orcid.org/0000-0002-2360-1170
Vanessa KleinDepartment of Internal Medicine Endocrine Unit, Shaare Zedek Medical Center Jerusalem affiliated with the Faculty of Medicine, Hebrew University, Jerusalem 3235, Israel.
Meir FrankelDepartment of Internal Medicine Endocrine Unit, Shaare Zedek Medical Center Jerusalem affiliated with the Faculty of Medicine, Hebrew University, Jerusalem 3235, Israel.ORCID https://orcid.org/0000-0001-5094-7719
Gheona AltarescuGenetic Department, Shaare Zedek Medical Center Jerusalem affiliated with the Faculty of Medicine, Hebrew University, Jerusalem 3235, Israel.ORCID https://orcid.org/0000-0003-2796-8399
Rachel BeeriGenetic Department, Shaare Zedek Medical Center Jerusalem affiliated with the Faculty of Medicine, Hebrew University, Jerusalem 3235, Israel.
Gabriel MunterDepartment of Internal Medicine Endocrine Unit, Shaare Zedek Medical Center Jerusalem affiliated with the Faculty of Medicine, Hebrew University, Jerusalem 3235, Israel.ORCID https://orcid.org/0000-0003-1789-5624
Shaare Zedek Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: Various genes have been associated with familial and sporadic primary hyperparathyroidism (PHPT), including activating mutations of the glial cells missing transcription factor 2 ( Objective: The aim of this study was to assess the prevalence of the Methods: The blood of 40 self-reported AJ patients with PHPT and 200 AJ controls was tested for the Results: Two (5%) PHPT patients and 3 (1.5%) controls were heterozygotes for the tested variant. Our patients were mostly (87.5%) sporadic cases. One of the heterozygote patients had familial PHPT; the other had 2 parathyroid adenomas, and the levels of his blood and urinary calcium were extremely high. Conclusion: Our results suggest that in AJ patients with sporadic, single-gland PHPT, the likelihood of the tested variant is low and genetic testing should be limited to those with familial PHPT or multiglandular disease.

Indexed as

activating mutationgeneticheterozygotesJewishparathyroid adenoma

Identifiers

PMID37362385
PMCPMC10289514
OpenAlexW4382182837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.